Semaglutide 10mg SM10

Semaglutide,Semaglutide peptide,peptide,lyophilized powder,research peptide,peptide vial,peptide raw material,factory supply,research grade peptide

Bulk Drug Intermediates

GLP-1R agonist

FDA-approved (Ozempic / Wegovy / Rybelsus)

Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.

Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).

Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI

NCT03548935; NCT03552757; NCT01720446; NCT02692716

Ozempic, Wegovy, Rybelsus (approved 2017-12-05)

CHEMBL2108724

DB13928

D10025

PubChem

NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)

Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.